DXP
Disease Modifying Therapy

Friday, June 1, 2018: 2:00 PM-4:00 PM
209 (Nashville Music City Center)
2:00 PM
Confirmed Disability Improvement in Patients with Relapsing Multiple Sclerosis in the Open-Label Extension Period of the Pooled Opera Trials
Robert T Naismith, MD, Washington University School of Medicine; Stephen L Hauser, MD, University of California; Bruno Brochet, MD, University of Bordeaux; Xavier Montalban, MD, PhD, Vall díHebron University Hospital; Jerry S Wolinsky, MD, McGovern Medical School, UTHealth; Laura Julian, PhD, Genentech, Inc.; Pablo Villoslada, MD, Genentech, Inc.; Fabian Model, PhD, F. Hoffmann-La Roche Ltd; Stanislas Hubeaux, MSc, F. Hoffmann-La Roche Ltd; Ludwig Kappos, MD, University of Basel

2:17 PM
Durable Improvements in MRI Disease Activity and Brain Volume Loss with Alemtuzumab in RRMS Patients: 7-Year Follow-up of Care-MS II
Daniel Pelletier, MD, Keck School of Medicine of University of Southern California; Anthony Traboulsee, MD, University of British Columbia; Michael Barnett, PhD, MD, University of Sydney; Giancarlo Comi, MD, University Vita-Salute San Raffaele; Jerome de Seze, MD PhD, University Hospital of Strasbourg; Alex Rovira, MD, Vall d'Hebron University Hospital; Sven Schippling, MD, Neuroimmunology and Multiple Sclerosis Research, University Hospital Zurich and University of Zurich; Luke Chung, MD, MPH, Sanofi; Nadia Daizadeh, PhD, Sanofi; Kunio Nakamura, PhD, Cleveland Clinic; Douglas L Arnold, MD, Montreal Neurological Institute, McGill University; on behalf of the CARE-MS II, CAMMS03409, and TOPAZ, Investigators, on behalf of the CARE-MS II, CAMMS03409, and TOPAZ Investigators

2:34 PM
Active RRMS Patients Show Disability Improvements in Each Functional System Following Treatment with Alemtuzumab: Results from Care-MS II Extension
Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute; Rany A Aburashed, DO, Institute for Neurosciences and Multiple Sclerosis; Raed Alroughani, MD, Amiri Hospital; Steven M Bromley, MD, FAAN, South Jersey MS Center; Dominique Dive, MD, PhD, University Hospital Centre of Liege; Guillermo Izquierdo, MD, Virgen Macarena University Hospital; Ho Jin Kim, MD, Research Institute and Hospital of National Cancer Center; Jan Lycke, MD, Sahlgrenska University Hospital; Richard AL Macdonell, MD, Austin Health and Florey Institute of Neuroscience and Mental Health; Carlo Pozzilli, MD, Sapienza University of Rome; Basil Sharrack, MD, PhD, Sheffield Teaching Hospitals NHS Foundation Trust; Patrick Vermersch, MD, University of Lille; Andreas Lysandropoulos, MD, PhD, Sanofi; Luke Chung, MD, MPH, Sanofi; Nadia Daizadeh, PhD, Sanofi; Heinz Wiendl, MD, University of Munster; on behalf of the CARE-MS II and CAMMS03409, Investigators, on behalf of the CARE-MS II and CAMMS03409 Investigators

2:51 PM
Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Developing Progressive Disease
Ralph H Benedict, PhD, University at Buffalo; Jerome de Seze, MD, PhD, University Hospital of Strasbourg; Stephen L Hauser, MD, University of California, San Francisco; Ludwig Kappos, MD, University Hospital Basel, University of Basel; Jerry S Wolinsky, MD, McGovern Medical School, UTHealth; Hanzhe Zheng, PhD, Genentech, Inc.; Shibeshih Belachew, MD, PhD, F. Hoffmann-La Roche Ltd; Laura Julian, PhD, Genentech, Inc.; Ashish Pradhan, MD, Genentech, Inc.; Fred Lublin, MD, Icahn School of Medicine at Mount Sinai; Stanley Cohan, MD, PhD, Providence Multiple Sclerosis Center

3:08 PM
Effects of Fingolimod on Magnetic Resonance Imaging Outcomes in Patients with Pediatric-Onset Multiple Sclerosis: Results from the Phase 3 Paradigms Study
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University; Brenda Banwell, MD, Children's Hospital of Philadelphia; Amit Bar-Or, MD, Neuroimmunology Unit, Montreal Neurological Institute and Hospital; Angelo Ghezzi, MD, Gallarate Hospital; Benjamin Greenberg, MD, MHS, UT Southwestern Medical Center; Emmanuelle Waubant, MD, PhD, Weill Institute for Neurosciences; Gavin Giovannoni, PhD, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK; Jerry S Wolinsky, MD, McGovern Medical School, UTHealth; Jutta Gaertner, MD, Department of Paediatrics and Adolescent Medicine, German Centre for Multiple Sclerosis in Childhood and Adolescence University Medical Centre; Kevin Rostasy, MD, Division of Paediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke; Lauren Krupp, MD, Pediatric MS Center, NYU Langone Medical Center; Marc Tardieu, MD, Bicetre Hospital; Wolfgang Brueck, MD, Department of Neuropathology, University Medical Centre; Tracy Stites, PhD, Novartis Pharmaceuticals Corporation; Gregory L Pearce, PhD, Novartis Pharmaceuticals Corporation; Martin Merschhemke, MD, PhD, Novartis Pharma AG; Tanuja Chitnis, MD, Partners Pediatric MS Center

3:25 PM
Efficacy and Safety of Ozanimod Versus Interferon Beta 1A
Bruce AC Cree, MD, PhD, Weill Institute for Neurosciences; Amit Bar-Or, MD, Center for Neuroinflammation and Therapeutics, and Multiple Sclerosis Division, University of Pennsylvania; Giancarlo Comi, MD, San Raffaele Scientific Institute, Vita-Salute San Raffaele University; Krzysztof W Selmaj, MD, PhD, Medical University of Lodz; Douglas L Arnold, MD, Montreal Neurological Institute, McGill University; Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center; Hans-Peter Hartung, MD, Heinrich-Heine University; Xavier Montalban, MD, Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall díHebron; Eva K Havrdova, MD, PhD, Charles University; James K Sheffield, MD, Receptos, a wholly owned subsidiary of Celgene; Kartik Raghupathi, PhD, Receptos, a wholly owned subsidiary of Celgene; Ludwig Kappos, MD, University of Basel; Jeffrey A Cohen, MD, Cleveland Clinic

3:42 PM
Phase 2 Multicenter Study Results of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Edward J. Fox, MD, PhD, Central Texas Neurology Consultants; Amy Lovett-Racke, PhD, Ohio State University Medical Center; Matilde Inglese, MD, PhD, Mount Sinai School of Medicine; Maria Petracca, MD, PhD, Icahn School of Medicine at Mount Sinai; Sibyl Wray, MD, Hope Neurology MS Center; Michael K Racke, MD, Wexner Medical Center, Ohio State University; Richard Shubin, MD, SC3 Research Group, Inc; Cary L Twyman, MD, Associates in Neurology PSC, Lexington, KY, USA; Michael Weiss, JD, TG Therapeutics, Inc; James Eubanks, PhD, TG Therapeutics, Inc; Koby Mok, PhD, TG Therapeutics, Inc; Wendy Su, PhD, TG Therapeutics, Inc

See more of: CMSC Abstracts